Printer Friendly

WISCONSIN PHARMACAL REPORTS FIRST QUARTER RESULTS

 WISCONSIN PHARMACAL REPORTS FIRST QUARTER RESULTS
 JACKSON, Wis., Jan. 31 /PRNewswire/ -- John Wundrock, R.Ph.,


president and CEO of Wisconsin Pharmacal Co., Inc. (NASDAQ: WPCI), today reported first quarter fiscal 1992 net revenues of $1,007,575, compared to $1,254,000 for the same period in fiscal 1991. The company posted a net loss of $457,411 or $0.14 per share for the quarter compared to a loss of $230,000 or $0.07 per share for the same quarter in fiscal 1991.
 Wundrock indicated that the majority of the company's current revenues are seasonal in nature with approximately 74 percent of the company's prior year net revenues being generated in the second and third quarters of the fiscal year. First quarter fiscal 1992 net revenues were lower due to reduced Repel Insect Repellent sales and Potable Aqua water purification tablet sales which in the first quarter of fiscal 1991 recorded increases of 242 percent and 212 percent over the prior year due primarily to end of season buying and early season shipments to two of the company's larger customers.
 During the first quarter of the fiscal year the company traditionally has reported net losses due to lower revenues resulting from the seasonality of its business. The effect of on income of lower sales volume net of higher gross margins ($98,000), increased research and new product development expenditures related to the company's female condom ($88,000) and a reduction in net interest income ($63,000) due to the utilization of the company's 1990 public offering proceeds in the development of the female condom and expansion of the business all contributed to the increase in the net loss for the quarter compared to the same quarter in the preceding year. The expenses related to the female condom include costs associated with the company's pre-marketing approval application submitted to the Food and Drug Administration in October 1991.
 Wundrock stated that the outlook for fiscal 1992 is positive. The January settlement of the chemical fish attractant patent lawsuit will allow the company to focus on the future.
 WISCONSIN PHARMACAL COMPANY, INC.
 CONDENSED CONSOLIDATED OPERATING RESULTS
 First Quarter of Fiscal 1992 1991
 Revenues
 Product sales $ 932,575 $1,179,000
 Royalties 75,000 75,000
 Total $1,007,575 $1,254,000
 Net loss $ (457,411) $ (230,000)
 Weighted average number of common &
 common equivalent shares outstanding 3,298,673 3,278,000
 Net loss per share $ (0.14) $ (0.07)
 NOTE:
 Included above as a charge to earnings
 are the following amounts of research
 and new product development expenditures
 related to the company's female condom
 product $ 155,041 $ 66,880
 -0- 1/31/92
 /CONTACT: John A. Wundrock, president and CEO of Wisconsin Pharmacal, 414-667-4121/
 (WPCI) CO: Wisconsin Pharmacal Company, Inc. ST: Wisconsin IN: MTC SU: ERN


JT -- NY078 -- 5859 01/31/92 19:03 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 31, 1992
Words:476
Previous Article:CMI CORPORATION WINS FINAL JUDGMENT AGAINST ASTEC INDUSTRIES
Next Article:CALPINE SELECTED BY LOS ANGELES DEPARTMENT OF WATER AND POWER TO NEGOTIATE FOR DEVELOPMENT OF 150 MW GEOTHERMAL FACILITY
Topics:


Related Articles
WISCONSIN PHARMACAL COMPANY REPORTS RECORD INCREASE IN FOURTH QUARTER AND FISCAL 1991 REVENUE
WISCONSIN PHARMACAL COMPANY FEMALE CONDOM APPLICATION SCHEDULED FOR ADVISORY PANEL REVIEW
WISCONSIN PHARMACAL ELECTS ROBERT E. BELLIN AND TOD R. HULLIN TO BOARD OF DIRECTORS
WISCONSIN PHARMACAL ANNOUNCES NEW CHARTEX AGREEMENT ON FEMALE CONDOM AND THIRD QUARTER RESULTS
WISCONSIN PHARMACAL COMPANY, INC. BELIEVES SELF MAGAZINE ARTICLE IS MISLEADING
WISCONSIN PHARMACAL PRESENTS INFORMATION REGARDING REALITY FEMALE CONDOM TO U.S. HOUSE OF REPRESENTATIVES COMMITTEE
WISCONSIN PHARMACAL COMPANY, INC. ANNOUNCES COMPLETION OF $11.9 MILLION OFFERING OF COMMON STOCK
AMERICAN STOCK EXCHANGE BEGINS TRADING WISCONSIN PHARMACAL COMPANY
AMEX BEGINS TRADING WISCONSIN PHARMACAL COMPANY STOCK
Sheffield Medical Technologies Reports First Quarter Financial Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters